New approach of the treatment of von Willebrand's disease during pregnancy.
OBJECTIVE
The aim of the study was to analyze the effectiveness of the application of DDAVP (desmopressin) and Hemate P with cryoprecipitate pre- and postpartum in patients with von Willebrand disease.


METHODS
We monitored 32 patients with von Willebrand disease during the study period 1993-2003. DDAVP was applied in the 36th/37th week of gestation and cryoprecipitate and fresh frozen plasma were applied 1 day before and 3 days after delivery. DDAVP treatment continued for 4 weeks. Factor VIII (Hemate P) at the day of delivery


RESULTS
No complications occurred in the studied population.


CONCLUSIONS
Precipitation of DDAVP, Hemate P, and cryoprecipitate may help in the treatment of pregnant women with von Willebrand disease.
Gojnic
Miroslava
M
Medical Faculty Belgrade, Institute of Gynecology and Obstetrics, Clinical Center of Serbia, University of Belgrade, 38 Milesevska Street, 11000, Belgrade, Serbia and Montenegro. gojagoya@EUnet.yu
Fazlagic
A
A
Likic
I
I
Stefanovic
A
A
Vidakovic
S
S
Pervulov
M
M
Petkovic
S
S
Mostic
T
T
Miljic
P
P
Bogdanovic
A
A
D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage; D036861:Delivery, Obstetric / Q000379:methods; D005169:Factor VIII / Q000008:administration & dosage / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000008:administration & dosage / Q000032:analysis; D005865:Gestational Age; D006490:Hemostatics / Q000008:administration & dosage; D006801:Humans; D010314:Partial Thromboplastin Time; D049590:Postpartum Period; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy / Q000628:therapy*; D011517:Prothrombin Time; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy / Q000628:therapy*
D006490:Hemostatics; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen; D003894:Deamino Arginine Vasopressin